A prescribing analysis covering 2017 through 2022 found that the number of patients receiving GLP-1 receptor agonists more than doubled, an increase exceeding 100 percent in five years. By 2022, at least twice as many individuals were prescribed these medications as in 2017, with uptake…
# GLP-1 Receptor Agonist Prescribing More Than Doubled From 2017 to 2022
The number of patients prescribed GLP-1 receptor agonists more than doubled between 2017 and 2022, growth of over 100 percent in a five-year span. By 2022, at least twice as many individuals were receiving these medications as in 2017. The rate of uptake accelerated steadily across the window, and the entire increase occurred within the 2017 to 2022 observation period.
The finding comes from an analysis of prescribing patterns covering those five years. The report measured the change in the number of patients prescribed the drug class and returned a headline result that is unusually clean for utilization data: a more-than-doubling of the patient base with no sign of a plateau. Because GLP-1 receptor agonists are a peptide-based drug class, a shift of this size carries weight beyond the clinic. It signals expanding clinical adoption of peptides at a scale that directly touches formulation priorities, delivery technology, and manufacturing planning.
The analysis does not specify which patient populations drove the increase, how prescribing varied by region, or which products, doses, and prescriber specialties were involved. Those gaps are real, and they define the limits of what the report can claim. The core fact stands: in five years, the number of patients prescribed this class of peptide medicines at least doubled.
The report's results reduce to a small set of figures:
A doubling in patient volume is a large shift for any established drug class, but the shape of the curve matters as much as its overall size. The report states that uptake accelerated steadily, which means the additions grew larger as the period progressed. Early in the window the class expanded at a slower pace; by 2022 it was adding patients at a faster one. That pattern is consistent with a therapeutic category crossing from early adoption into broad clinical use, rather than a single spike that faded.
The confinement of the growth to one study window deserves attention. The 2017 baseline and the 2022 endpoint come from the same analysis, so the comparison does not require stitching together data sets collected with different methods. Nothing in the report suggests a change in coding or counting that would inflate the later figure. At the same time, no data beyond 2022 was included, so the analysis cannot say whether the curve continued upward, flattened, or turned over after the period closed.
The study design is an analysis of prescribing patterns spanning 2017 through 2022. Its endpoint is the change in the number of patients prescribed GLP-1 receptor agonists, and its duration is five years. The report does not specify the patient population or the sample size behind the counts, so the absolute scale of the data is unknown. That omission does not change what the endpoint measures: the number of individuals with prescriptions for the class in each year, compared across the period.
A prescribing-patterns analysis measures utilization, not clinical outcomes. It can document that more patients received these drugs; it cannot establish that the drugs worked, that they were tolerated, or that the prescriptions were appropriate for the conditions treated. The design also cannot separate the drivers of the increase. New indications, new products, changes in reimbursement, broadening of prescriber specialties, and patient demand could each have contributed, and the analysis as described cannot attribute the growth among them.
What the design can demonstrate is narrower but still significant: acceptance of the class by prescribers and patients, measured by prescription counts, more than doubled in five years. That is a utilization fact, and utilization facts matter for planning. Research groups deciding where to direct peptide method development, manufacturers weighing capacity expansion, and clinicians anticipating formulary pressure all rely on the same question the analysis answers: how quickly is the class being adopted? For 2017 to 2022, the answer is that adoption at least doubled and kept accelerating.
GLP-1 receptor agonists are peptide-based medicines, and the biology they exploit explains why the class has become so widely prescribed. Endogenous glucagon-like peptide-1 is an incretin hormone released from intestinal L cells in response to nutrient intake. It binds to the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, and potentiates glucose-dependent insulin secretion: as blood glucose rises, receptor signaling amplifies insulin release, and when glucose is low, secretion is not driven. That glucose dependence is the reason the class carries a relatively low intrinsic risk of hypoglycemia compared with insulin or sulfonylureas.
The receptor is not confined to the pancreas. GLP-1 receptor signaling suppresses glucagon release from pancreatic alpha cells, slows gastric emptying, and acts on receptors in the hypothalamus and brainstem to reduce appetite and promote satiety. Those actions underlie the class's effects on body weight and postprandial glucose excursions, and they explain why these drugs have found use beyond glycemic control in type 2 diabetes, including in obesity management and cardiovascular risk reduction.
Native GLP-1 is short-lived, with a plasma half-life of roughly two minutes, because the enzyme DPP-4 cleaves it rapidly and the kidney clears it. Therapeutic agents in the class are therefore engineered rather than administered as the native hormone. The peptides used clinically carry amino acid substitutions that resist DPP-4 cleavage, and many are derivatized with fatty acid moieties that bind albumin and extend circulation time from minutes to days. The result is a set of injectable peptides, joined more recently by oral formulations that rely on absorption-enhancer technology, that sustain receptor engagement over a dosing interval of a day or longer. The prescribing surge between 2017 and 2022 rests on that foundation of peptide engineering: sequence design, half-life extension, and formulation science that turned a fragile gut hormone into a practical medicine.
For clinicians, a more-than-doubling of the patient base changes the practical demands of prescribing. GLP-1 receptor agonists are no longer a specialty niche. They are a mainstream prescription class whose titration schedules, dosing devices, and adverse-effect profiles now sit in primary care as well as endocrinology. The analysis does not identify prescriber specialties, but the scale of the increase makes it probable that a broad range of clinicians now manages these drugs, with consequences for education, formulary management, and patient monitoring.
For peptide researchers, the five-year trend points to specific priorities. Formulation science becomes more important as the patient base grows, because the class is moving toward presentations that are convenient and stable: prefilled injection devices, room-temperature-stable formulations, and oral delivery systems that protect the peptide from gastrointestinal degradation while enhancing absorption. Delivery science is the binding constraint on patient acceptance for a peptide class, and a doubling of the prescribing base strengthens the case for investing in it.
Manufacturing scalability is the third pressure point. Peptide drugs are produced by solid-phase peptide synthesis, recombinant expression, or hybrid approaches, and they require purification, lyophilization, fill-finish processing, and cold-chain distribution that are more demanding than small-molecule production. A patient base that at least doubled in five years implies a matching increase in active pharmaceutical ingredient demand, and that increase strains synthesis capacity, analytical testing, and supply logistics. The question the field now faces is not whether these drugs work; it is whether production and delivery capacity can keep pace with a prescribing curve that accelerated steadily through 2022.
The analysis leaves the most granular questions open. It does not identify the specific GLP-1 receptor agonist products that contributed to the increase, so it cannot distinguish between growth driven by a single dominant product and growth spread across several. It does not specify patient populations, so it cannot separate prescribing for type 2 diabetes from use in obesity management or cardiovascular risk reduction, each of which expanded as clinical evidence accumulated in recent years. It does not report year-by-year rates, so the steady acceleration is described qualitatively rather than quantified. And it provides no regional detail, leaving open whether the growth was concentrated in particular health systems or countries.
The report flags the same gaps. Exact patient populations and regional variations are not specified. No data beyond the 2017 to 2022 range was included. Specific products, doses, and prescriber details are not identified. These limitations define what the report is: a class-level utilization signal, not a product-level or patient-level analysis. It establishes that the class doubled its patient reach in five years, which is a substantial finding in its own right. It does not establish which patients benefited, which products carried the load, or whether the trend continued after 2022.
What would settle those questions is prescription-level or aggregated longitudinal data stratified by indication, product, geography, and prescriber specialty, ideally linked to diagnosis codes so the patient populations can be characterized. Year-by-year counts between 2017 and 2022 would convert the qualitative description of acceleration into a curve that can be modeled. Post-2022 data would show whether the increase represents a durable shift or a peak. Those additions, rather than any new efficacy trial, are what would turn this utilization signal into a complete picture of how the GLP-1 receptor agonist class is being adopted by the health system.
Peptides referenced: Glucagon, GLP-1.
Related reading: Novo Nordisk Lawsuit Alleges Eli Lilly GLP-1 Ads Are Misleading, GLP-1 Finding Warned by Doctors May Increase Smell Loss Risk, Pharma Giants Dispute Over Obesity Drug Advertising, Wegovy Maker Files Suit Against Eli Lilly Over False GLP-1 Ads.